31,448 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,448 shares of the company’s stock, valued at approximately $721,000.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Guardant Health by 2.7% during the first quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company’s stock worth $235,925,000 after acquiring an additional 305,372 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Guardant Health in the first quarter valued at about $75,000. Adalta Capital Management LLC lifted its holdings in shares of Guardant Health by 15.6% in the first quarter. Adalta Capital Management LLC now owns 71,023 shares of the company’s stock valued at $1,465,000 after purchasing an additional 9,565 shares in the last quarter. Beck Bode LLC raised its position in Guardant Health by 42.6% in the 1st quarter. Beck Bode LLC now owns 203,596 shares of the company’s stock valued at $4,200,000 after buying an additional 60,851 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in Guardant Health by 7.0% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 152,986 shares of the company’s stock valued at $3,156,000 after acquiring an additional 10,000 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Activity

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Guardant Health Trading Up 5.4 %

Shares of NASDAQ:GH opened at $32.65 on Friday. The company has a market capitalization of $4.03 billion, a P/E ratio of -7.70 and a beta of 1.11. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The business’s 50 day simple moving average is $24.22 and its 200 day simple moving average is $26.83. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $37.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the previous year, the business posted ($0.73) EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. On average, research analysts anticipate that Guardant Health, Inc. will post -3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GH. UBS Group lifted their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. Piper Sandler boosted their price target on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Leerink Partners lowered their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Craig Hallum increased their price target on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. boosted their price target on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.